Evidence map›Paper›PMID 35008842›Full record

ArticleInternational journal of molecular sciences2021

Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders.

Jingjing Liu, Wenyang Zhao, Chun Li, Tongyu Wu, Liang Han, Zhuozhou Hu, Xiangxiang Li, Jing Zhou, Xinping Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Impacts of Oxylipins on ischemic stroke: from pathophysiology to clinical phenotypes.Metabolomics : Official journal of the Metabolomic Society · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jingjing LiuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Wenyang ZhaoSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Chun LiSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Tongyu WuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Liang HanSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Zhuozhou HuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Xiangxiang LiSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Jing ZhouSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Xinping ChenSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.ORCID 0000-0002-7490-9036
Lanzhou University · CN

Funding

"Double First-Class" university project funding from Lanzhou University 561119201Fundamental Research Funds for the Central Universities lzujbky-2021-kb05
6 · The paper itself

Abstract

Gastrointestinal disease is the most common health concern that occurs due to environmental, infectious, immunological, psychological, and genetic stress. Among them, the most frequent diseases are gastric ulcer (GU) and ulcerative colitis (UC). DSS-induced UC and ethanol-stimulated GU models resemble the pathophysiology of human gastrointestinal disease. The current study was designed to explore the anti-oxidation, anti-inflammation, anti-cell death properties of terazosin, an α-adrenergic receptor antagonist, in vivo and in vitro. Our results indicate that terazosin dramatically activates Pgk1, and upregulates glycose metabolism, evidenced by the enhanced ATP production and higher LDH enzymatic activity. Also, terazosin significantly enhances p-AKT expression and inhibits NF-κB p65 activation through abrogating the phosphorylation of IKBα, as well as lowers Caspase-1 and GSDMD expression. The findings in this study demonstrate that terazosin exhibits anti-inflammatory effects by downregulating NF-κB-GSDMD signal pathway, along with enhancing glycolysis for gastrointestinal disease treatment. Meanwhile, we also find terazosin ameliorates ethanol-induced gastric mucosal damage in mice. Collectively, as a clinical drug, terazosin should be translated into therapeutics for gastrointestinal disease soon.

Indexed as

ApoptosisCaco-2 CellsCell SurvivalColitisCytokinesDeoxyglucoseDextran SulfateGastric MucosaGastrointestinal DiseasesGlucoseHumansHydrogen PeroxideInflammation MediatorsLactic AcidMalondialdehydeModels, BiologicalCytokinesDeoxyglucoseDextran SulfateGlucoseHydrogen PeroxideInflammation MediatorsLactic AcidMalondialdehydePeroxidasePhosphoglycerate KinasePrazosinSuperoxide DismutaseTerazosinanti-inflammationcell deathgastrointestinal diseasePgk1terazosin

Identifiers

PMID35008842
PMCPMC8745693
OpenAlexW4205196795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.